Week In Review: Innovent Acquires GenFleet's KRAS G12C Oncology Candidate In $312 Million Deal

Suzhou Innovent acquired greater China rights to GenFleet's lead KRAS G12C oncology candidate in a $312 million agreement. Innovent will pay $22 million upfront and make up to $240 million in milestone payments.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.